DYAX: Dyax Corp. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DYAX: Dyax Corp.

DYAX 38.41

0.0%

Jan 25 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mcbio who wrote (180)	11/23/2008 2:37:03 AM
From: idos	Read Replies (1) of 197

Cinryze was approved as an orphan drug for prophylactic treatment of HAE and since DX-88 is indicated for acute setting, it will not be blocked by the orphan exclusivity. Also, DX-88 has a different mechanism of action that makes it eligible for approval even for prophylactic treatment, but that is very unlikely due to its short half life. siliconinvestor.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next